CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery
- 31 December 1993
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (7), 966-971
- https://doi.org/10.1016/s0959-8049(05)80203-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- CA-125 in ovarian cancer: Relation between half-life, doubling time and survivalEuropean Journal of Cancer and Clinical Oncology, 1991
- Does intraperitoneal CA-125 reflect disease status?Gynecologic Oncology, 1991
- Carcinoma-associated mucin serum markers CA M26 and CA M29: Efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervixInternational Journal of Cancer, 1991
- Serum Levels of CA 125 in Patients with Gastrointestinal CancersTumor Biology, 1989
- The clinical significance of pre-operative serum CA 125 in ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1986
- Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive SystemThe Lancet Healthy Longevity, 1986
- Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour markerBritish Journal of Cancer, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Presentation of therapeutic results in carcinoma of the female pelvis: Experience of the Annual Report on the Results of Treatment in Carcinoma of the Uterus, Vagina, and OvaryGynecologic Oncology, 1976